Drug interactions
Elagolix + Linagliptin-metformin
Severity: Minor
Elagolix and Linagliptin-metformin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Elagolix inhibits P-gp and weakly induces CYP3A4, so effects on linagliptin exposure may go in either direction and are probably small. No clinically important change in glycemic control is expected.
What this interaction means in plain words
Elagolix and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Elagolix belongs to Musculoskeletal; Linagliptin-metformin belongs to Endocrine.
Why it happens
Elagolix inhibits P-gp and induces CYP3A4, with opposing effects on linagliptin exposure.
What to do
No dose adjustment is needed; monitor glycemic response if therapy is changed.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Elagolix and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Elagolix
- Cyclosporin + Elagolix Contraindicated
- Elagolix + Gemfibrozil Contraindicated
- Desogestrel-ethinyl estradiol + Elagolix Major
- Elagolix + Erythromycin Major
- Elagolix + Ethinyl estradiol-drospirenone Major
- Elagolix + Ethinyl estradiol-levonorgestrel Major
Frequently asked questions
Can I take Elagolix with Linagliptin-metformin?
MediHelp rates the interaction as minor. Elagolix and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Elagolix inhibits P-gp and weakly induces CYP3A4, so effects on linagliptin exposure may go in either direction and are probably small. No clinically important change in glycemic control is expected.
How serious is the interaction between Elagolix and Linagliptin-metformin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is needed; monitor glycemic response if therapy is changed.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
